Objective We conducted a multicenter phase II trial to assess the efficacy and toxicity of docetaxel (D) and carboplatin (C) combination as neoadjuvant therapy for stage II or III breast cancer (BC). clinical response (15 cCR 28 cPR). Nine SIB 1757 (16% 90 CI :10%-28%) patients had pCR. Four of 9 (44%) pts with TNBC… Continue reading Objective We conducted a multicenter phase II trial to assess the